MannKind Corporation (MNKD)
| Market Cap | 1.03B |
| Revenue (ttm) | 81.37M |
| Net Income (ttm) | -79.28M |
| Shares Out | 251.26M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,958,530 |
| Open | 3.98 |
| Previous Close | 3.92 |
| Day's Range | 3.88 - 4.18 |
| 52-Week Range | 3.12 - 6.25 |
| Beta | 1.75 |
| Analysts | Buy |
| Price Target | 6.25 (+53.2%) |
| Earnings Date | Nov 9, 2021 |
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyva...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for MannKind stock is "Buy." The 12-month stock price forecast is 6.25, which is an increase of 53.19% from the latest price.
News
MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference
DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocr...
MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases
DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocr...
MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference
WESTLAKE VILLAGE, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients w...
MannKind (MNKD) Reports Q3 Loss, Tops Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 20.00% and 8.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: MannKind Q3 Earnings
MannKind (NASDAQ:MNKD) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement.
Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic prod...
MannKind Presents Data at 21st Annual Diabetes Technology Meeting
WESTLAKE VILLAGE, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative medicines for patients with endocrine and orphan lung dis...
MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021
WESTLAKE VILLAGE, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 third quarter financial results and its management will host a conference call to dis...
Will MannKind (MNKD) Report Negative Q3 Earnings? What You Should Know
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Shares of MannKind Corporation Are Falling This Morning
Investors are hyperventilating after a delay for its inhaled medicine.
MNKD Stock: The Disappointing FDA News That Has MannKind Shares Diving Today
MannKind (MNKD) stock is taking a beating on Monday after releasing an update to investors concerning news from the FDA for Tyvaso DPI. The post MNKD Stock: The Disappointing FDA News That Has MannKind ...
MannKind's stock falls 18% after FDA says it will not approve application for hypertension drug
Shares of MannKind Corp. MNKD, -17.68% tumbled 18.3% in trading on Monday after the company said the Food and Drug Administration would not approve a pulmonary arterial hypertension treatment it is deve...
Why MannKind Shares Are Falling Today
MannKind Corp (NASDAQ: MNKD) is trading significantly lower Monday morning after the company announced the FDA issued a complete response to United Therapeutics regarding the New Drug Application for Ty...
FDA Declines MannKind - United Therapeutics' Formulated Treprostinil For Lung Disease
The FDA has issued a complete response to United Therapeutics Corporation (NASDAQ: UTHR) regarding the marketing application for Tyvaso DPI for pulmonary arterial hypertension (PAH) and pulmonary hypert...
Progress Update on Tyvaso DPI™ New Drug Application
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Oct. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic prod...
Do Options Traders Know Something About MannKind (MNKD) Stock We Don't?
Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.
MannKind Announces First Patient Enrolled In Inhale-1 Study Of Afrezza® In Pediatric Population
WESTLAKE VILLAGE, Calif., Oct. 4, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with e...
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informatio...
Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 29, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic pro...
MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference
WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients ...
Mannkind Corporation Participating at Upcoming Conferences
WESTLAKE VILLAGE, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients ...
MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
WESTLAKE VILLAGE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients ...
8 Best Penny Stocks To Buy Right Now According To Insiders
Insiders are buying these penny stocks right now. Should you?
Best Penny Stocks To Buy Right Now? 5 To Watch Before September
Looking for penny stocks to buy now? The post Best Penny Stocks To Buy Right Now?